Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Harry P. Erba(Michigan Center for Translational Pathology), Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Stephen Dale(Kura Oncology (United States)), Stéphane de Botton(Université Paris-Saclay), Jessica K. Altman(Northwestern University), Stephen A. Strickland(Vanderbilt University), James M. Foran(Memorial Sloan Kettering Cancer Center), Gary J. Schiller(Fred Hutch Cancer Center), Blake Tomkinson(Kura Oncology (United States)), Maria R. Baer(University of Maryland, Baltimore), Marilyn Tabachri(Kura Oncology (United States)), Kristen Pettit(University of Michigan), Marina Kremyanskaya(Tisch Cancer Institute), Mrinal M. Patnaik(Mayo Clinic), Mollie Leoni(Kura Oncology (United States)), Pau Montesinos(Instituto de Salud Carlos III), Ghayas C. Issa(The University of Texas MD Anderson Cancer Center), Amir T. Fathi(University of Southern California)
Cited by 71
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k